Simcere Pharmaceutical Group

Activities: Ingredients Research & Development Pharmaceutical

Trending Articles

  1. Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222 Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
  2. CordenPharma & GENEPEP collaborate to leverage peptide drug substance discovery The partnership has facilitated the expedition of the development, discovery and manufacturing of peptides for early clinical phase
  3. ISPE announces 2024 Facility of the Year Awards category winners The awards programme recognises pharmaceutical companies that are the 'best' in the industry for innovation, operations, digitalisation, supply chain and social impact
  4. Tabletability, compactability and compressibility: What’s the difference? To patients and consumers, tablets are a simple and convenient dosage form, but the science behind compressing a block of particles or granules into a single tablet can be...
  5. Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for...

Upcoming event

Making Pharmaceuticals

23–24 April 2024 | Exhibition | Coventry, UK See all

Related Content

Finance

Merck and Simcere dissolve cardiovascular and metabolic joint venture

An explosion in the online market for drugs in China cited as a key factor in the decision

Simcere Pharmaceutical Group appoints Chief Scientific Officer

Dr Zang Jingwu to lead research and development team
Finance

Chinese drug majors look to the West to build brands

In China, large drug manufacturers are seeking partnerships, mergers and acquisitions with Western companies, writes Asia correspondent A Nair

Buyouts prove popular in China

Chinese pharma companies turning to private capital

Simcere appoints a chief executive

Hongquan Liu takes up the position next month
Research & Development

Bristol-Myers Squibb announces second pact with Simcere

The firms will co-develop BMS-795311, a preclinical small molecule CETO inhibitor
Finance

Merck and Simcere agree joint venture

Will initially offer drugs for cardiovascular and metabolic diseases
Subscribe now